Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Fig. 1

Each panel displays data for a single patient (indicated at the top of each graph) at baseline (Day 0) and after samalizumab dosing at the indicated time points. For simplicity, no more than the first 4 dosing cycles are shown. a. Percent change from baseline in CLL CD200 expression (mean channel fluorescence (MFI)) in CLL patients. b. Percent change from baseline in CD200+ CD4+ T cells (%) in CLL and MM patients

Back to article page